As part of this project, Arteriocyte has been tasked and funded for the development, optimization, and pre-clinical evaluation of a proprietary bandage that is formulated to deliver growth factors, antimicrobial and hemostatic agents in optimal concentrations to help maintain tissue viability in severely injured limbs. The finished product is expected to be shelf stable at room temperature, easy to apply in the battlefield, and easy to integrate with other components of the ACCSIL bandage currently in development by other research organizations.
A prototype of the trauma dressing has already been completed, and the company expects to finish in-vitro optimization studies, and pre-clinical safety-toxicity and efficacy studies as per ISO and ASTM standards and guidelines before the end of the year. Future optimization of the growth factor dressing will allow for a next generation product that will co-deliver antimicrobial components and clotting agents in addition to a sustained release of growth factors for maintaining tissue viability. Arteriocyte will collaborate with the ACCSIL team to integrate all components into a final product. The status of the development efforts was presented at the Annual Review meeting conducted by ONR in July 2016, and at the Military Health System Research Symposium (MHSRS) in August 2016.
"The ACCSIL project represents another advance towards creating novel technologies to improve treatment for our battlefield injured. We are honored to be invited by ONR to help create the first advanced wound dressing that co-delivers growth factors, antimicrobial and hemostatic agents to improve tissue viability and speed wound healing," said Arteriocyte CEO, Don Brown.
Arteriocyte, a leading clinical stage biotechnology company, is dedicated to developing novel cellular products and medical devices to help patients heal faster. Arteriocyte leverages its expertise in stem cell and tissue engineering to develop a broad portfolio of cell based therapeutics to improve patient outcomes.
For Inquiries about ACCSIL or product development questions: Caitlin Smith (216)456-9654, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arteriocyte-presents-its-update-on-development-of-bioactive-coating-to-maintain-tissue-viability-in-acute-battlefield-injuries-for-the-accsil-bandage-program-300348639.html
SOURCE Arteriocyte, Inc.